Boston, MA – [Insert Date of Publication] – Airway Therapeutics has successfully closed a significant $50 million equity financing round, a crucial step in propelling its promising therapeutic candidate, zelpultide alfa, through the critical stages of late-stage clinical development. The substantial funding infusion is earmarked to support the ongoing Phase IIb/III clinical trial aimed at preventing bronchopulmonary dysplasia (BPD) in very preterm infants, a vulnerable population with a dire unmet medical need.
n
This latest financial milestone comprises $26 million from a previously completed SAFE (Simple Agreement for Future Equity) financing, augmented by an additional $24 million raised through a newly established Series E-2 equity round. The overwhelming support from existing investors, with approximately 94% participating in the Series E-2 fundraising, underscores a strong vote of confidence in Airway Therapeutics’ scientific vision, its dedicated team, and the transformative potential of zelpultide alfa.
n
A Critical Advance in Neonatal Respiratory Health
n
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects newborns, particularly those born prematurely, who require prolonged mechanical ventilation and oxygen therapy. It is characterized by inflammation and scarring of the lungs, leading to long-term respiratory problems and increased susceptibility to infections. Currently, there are no approved preventive therapies for BPD, leaving clinicians and families with limited options to mitigate its devastating effects.
n
Zelpultide alfa represents a novel approach to BPD prevention. It is a recombinant human surfactant protein D (rhSP-D), a naturally occurring protein in the lungs that plays a vital role in immune defense and lung homeostasis. Preclinical and early-stage clinical studies suggest that zelpultide alfa can modulate immune responses within the developing lungs, enhance the clearance of pathogens, and help maintain the delicate balance of surfactant, a substance essential for lung function. The drug candidate has demonstrated a favorable safety and tolerability profile in a prior Phase Ib study, paving the way for its evaluation in larger, more robust trials.
n
Strategic Funding to Fuel Late-Stage Development
n
The $50 million in new capital will be strategically deployed to ensure the seamless execution of the ongoing Phase IIb/III clinical trial. Beyond direct trial costs, a significant portion of the funds will be allocated to essential chemistry, manufacturing, and controls (CMC) activities, as well as critical analytical work. These elements are paramount for advancing the zelpultide alfa program through late-stage development and preparing for regulatory submissions, including the Biologics License Application (BLA).
n
"We are extremely pleased by the strong participation and continued support of our existing investors," stated Marc Salzberg, Chairman and CEO of Airway Therapeutics. "Their commitment, with approximately 94% of our current cap table participating in the Series E-2 round, reflects their confidence in Airway, our team, and the immense potential of zelpultide alfa. With this round, we are well-positioned to maintain momentum across our late-stage clinical program as we evaluate zelpultide alfa for the prevention of BPD in very preterm infants, a population with significant unmet medical need and no approved preventive therapies."
n
The financial strength provided by this funding round is expected to enable Airway Therapeutics to navigate the complexities of late-stage clinical trials and manufacturing scale-up with discipline and efficiency. Alan Wolk, CFO and COO of Airway Therapeutics, emphasized the strategic importance of this financing. "This round further solidifies Airway’s financial position as we execute the ongoing Phase IIb/III clinical trial and prepare for the program’s next important development milestones," Wolk commented. "The proceeds provide us with the capital to support the clinical study as well as the CMC and BLA readiness analytical work necessary to advance zelpultide alfa through late-stage development in a disciplined and efficient manner."
n
A Clear Path Forward: Key Milestones and Investor Confidence
n
The successful completion of this financing round provides Airway Therapeutics with a clear runway to achieve critical upcoming milestones. A particularly significant event on the horizon is the anticipated interim analysis of the Phase IIb portion of the trial. The company expects to complete this analysis by the end of the second quarter (Q2) of 2027. This interim analysis will provide crucial insights into the efficacy and safety of zelpultide alfa, potentially informing decisions about the trial’s continuation and design as it progresses into its Phase III component.
n
The investor base for this latest financing round includes notable entities such as Cincinnati Children’s, a renowned pediatric hospital and research institution, alongside several prominent family offices. The participation of Cincinnati Children’s is particularly significant, given their deep expertise in pediatric care and neonatology, and their potential to contribute valuable clinical insights and support. The involvement of family offices further signals a robust belief in the long-term growth potential and the significant impact zelpultide alfa could have on infant health.
n
The Science Behind Zelpultide Alfa: A Multifaceted Approach to Lung Health
n
The therapeutic rationale for zelpultide alfa is rooted in its ability to mimic and enhance the natural protective functions of surfactant protein D. SP-D is a key component of the innate immune system in the lungs. It acts as a pattern recognition molecule, binding to conserved microbial structures and facilitating their clearance by immune cells. Furthermore, SP-D has been shown to modulate inflammatory responses, dampening excessive inflammation that can contribute to lung injury. In the context of BPD, preterm infants often have immature lungs with compromised immune defenses and a predisposition to inflammation.
n
Zelpultide alfa is engineered as a highly purified, recombinant form of human SP-D, ensuring consistent quality and dose. By administering zelpultide alfa, Airway Therapeutics aims to bolster the infant’s natural lung defenses, reduce the inflammatory cascade that leads to BPD, and potentially improve the overall structural and functional development of the lungs. The drug candidate’s mechanism of action is designed to be both protective and restorative, addressing the complex pathophysiology of BPD.
n
The Journey from Phase Ib to Phase IIb/III: Building on Success
n
The ongoing Phase IIb/III trial builds upon the positive results of a preceding Phase Ib study. In this earlier study, zelpultide alfa was administered to a small group of infants, and the primary endpoints focused on safety and tolerability. The favorable outcomes from this Phase Ib trial provided the necessary data to advance into the larger, more comprehensive Phase IIb/III study. This sequential approach, moving from safety assessments to efficacy evaluations, is a standard and rigorous pathway for drug development, ensuring that potential therapies are thoroughly vetted before reaching broader patient populations.
n
The design of the Phase IIb/III trial is critical. The Phase IIb component will likely focus on evaluating different doses of zelpultide alfa and further assessing its efficacy in preventing BPD, while the Phase III component will be a larger, pivotal study designed to confirm efficacy and safety in a statistically significant patient population, ultimately supporting regulatory approval. The interim analysis at the end of Q2 2027 will be a crucial checkpoint, allowing researchers and the company to assess early trends and make informed decisions about the trial’s trajectory.
n
Addressing a Critical Global Health Challenge
n
The prevention of BPD is not only a significant clinical challenge but also a public health imperative. BPD can lead to lifelong respiratory issues, increased healthcare utilization, and a reduced quality of life for affected children and their families. The economic burden associated with managing chronic BPD is also substantial, encompassing extended hospital stays, frequent readmissions, and ongoing medical care.
n
Airway Therapeutics’ pursuit of a preventive therapy for BPD addresses this multifaceted challenge head-on. By developing a treatment that can be administered shortly after birth to very preterm infants, the company aims to significantly reduce the incidence and severity of BPD, thereby improving long-term health outcomes and potentially alleviating the associated healthcare costs. The successful development of zelpultide alfa could represent a paradigm shift in the management of prematurity-related lung complications.
n
Implications for the Future of Neonatal Care
n
The successful progression of zelpultide alfa through late-stage clinical trials and its potential approval would have profound implications for neonatal intensive care units (NICUs) worldwide. It would offer clinicians a much-needed tool to proactively protect vulnerable infants from the ravages of BPD. This could translate into shorter hospital stays, reduced need for mechanical ventilation, fewer long-term respiratory sequelae, and ultimately, a better start in life for thousands of infants born too soon.
n
The investment in zelpultide alfa by Airway Therapeutics, coupled with the strong support from its investors, highlights the significant scientific and commercial potential that the biotechnology sector sees in addressing critical unmet medical needs in pediatric populations. As the company moves towards its next key milestones, the medical community and patient advocacy groups will be watching with keen interest, hopeful that zelpultide alfa can indeed deliver on its promise to revolutionize BPD prevention. The journey is far from over, but with this substantial financial backing and a clear development path, Airway Therapeutics is well-equipped to pursue its vital mission.
nnnnnn
